ABHD6 and fatty liver disease: Given its recent links to systemic (glucose) metabolism (1), it will be interesting to see how dysregulated lyso-PS signaling in the liver might contribute toward metabolic conditions such as hepatic steatosis or systemic insulin resistance (modulated by ABHD6 activity), and crosstalk with other lipid pathways involved in such human diseases.